RA0356

antibody from Oursmab

Targeting: IL1B IL-1B, IL1-BETA, IL1F2

Immunocytochemistry

Flow cytometry

Functional assay

Antibody data

Submit

Validation data

Product number: RA0356 - Provider product page
Provider: Oursmab
Product name: Canakinumab (Biosimilar Reference Antibody) (IL1B)
Antibody type: Monoclonal
Description: Canakinumab is a fully human monoclonal antibody developed as a targeted anti-inflammatory therapy. It is marketed under the brand name Ilaris and is approved for the treatment of several rare autoinflammatory syndromes characterized by overproduction of interleukin-1¦Â (IL-1¦Â), including Cryopyrin-Associated Periodic Syndromes (CAPS), Tumor Necrosis Factor Receptor¨CAssociated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), and Familial Mediterranean Fever (FMF). Notably, canakinumab gained significant attention for its role in the landmark CANTOS trial, which demonstrated its ability to reduce cardiovascular events in patients with a history of myocardial infarction and elevated high-sensitivity C-reactive protein (hsCRP), independently of lipid lowering.
Reactivity: Human
Isotype: IgG
Vial size: 100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg
Concentration: Bottled at the concentration indicated on the vial.
Storage: Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

IL1B protein structure - RA0356 shown in red.